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Morbidity and Mortality Weekly Report

Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory
Committee on Immunization Practices, 2015
J. Erin Staples, MD1; Joseph A. Bocchini Jr., MD2,3; Lorry Rubin, MD2,4; Marc Fischer, MD1 (Author affiliations at end of text)

On February 26, 2015, the Advisory Committee on
Immunization Practices (ACIP) voted that a single primary
dose of yellow fever vaccine provides long-lasting protection
and is adequate for most travelers (1). ACIP also approved
recommendations for at-risk laboratory personnel and certain
travelers to receive additional doses of yellow fever vaccine
(Box). The ACIP Japanese Encephalitis and Yellow Fever
Vaccines Workgroup evaluated published and unpublished
data on yellow fever vaccine immunogenicity and safety. The
evidence for benefits and risks associated with yellow fever
vaccine booster doses was evaluated using the Grading of
Recommendations, Assessment, Development, and Evaluation
(GRADE) framework (2,3). This report summarizes the evidence considered by ACIP and provides the updated recommendations for yellow fever vaccine booster doses.

Yellow Fever Epidemiology and Risk for Disease
in Travelers
Yellow fever is a mosquito-borne viral disease that is endemic
to sub-Saharan Africa and tropical South America. Worldwide,
yellow fever virus causes an estimated 200,000 cases of clinical
disease and 30,000 deaths annually (4). Clinical disease ranges
Recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on
Immunization Practices (ACIP). ACIP is chartered as a federal
advisory committee to provide expert external advice and guidance to the Director of the Centers for Disease Control and Prevention (CDC) on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of
the United States. Recommendations for routine use of vaccines
in children and adolescents are harmonized to the greatest extent
possible with recommendations made by the American Academy
of Pediatrics (AAP), the American Academy of Family Physicians
(AAFP), and the American College of Obstetricians and Gynecologists (ACOG). Recommendations for routine use of vaccines in
adults are harmonized with recommendations of AAFP, ACOG,
and the American College of Physicians (ACP). ACIP recommendations approved by the CDC Director become agency guidelines
on the date published in the Morbidity and Mortality Weekly Report (MMWR). Additional information regarding ACIP is available at http://www.cdc.gov/vaccines/acip.

from a mild, nonspecific febrile illness to severe disease with
jaundice and hemorrhage. The case-fatality ratio for severe yellow fever is 20%–50% (5). Because no specific treatment exists,
prevention through vaccination is critical to reduce morbidity
and mortality from yellow fever virus infection.
The risk of a traveler acquiring yellow fever varies based on
season, location, activities, and duration of their travel. For a
2-week stay, the estimated risk for illness attributed to yellow
fever for an unvaccinated traveler to West Africa is 50 cases per
100,000 population; for South America, the risk for illness is
five cases per 100,000 population (6).

Yellow Fever Vaccine Recommendations and
International Health Regulations Requirements
Yellow fever vaccine is recommended for persons aged
≥9 months who are traveling to or living in areas with risk
for yellow fever virus transmission (7). International Health
Regulations allow countries to require proof of yellow fever
vaccination from travelers entering their country (8). These
requirements are intended to minimize the potential importation and spread of yellow fever virus. Currently, International
Health Regulations specify that a dose of yellow fever vaccine
is valid for 10 years. Therefore, at present, travelers to countries
with a yellow fever vaccination entry requirement must have
received a dose of yellow fever vaccine within the past 10 years.
Recent changes to yellow fever vaccine recommendations. In April 2013, the World Health Organization Strategic
Advisory Group of Experts on Immunization concluded that a
single primary dose of yellow fever vaccine is sufficient to confer
sustained immunity and lifelong protection against yellow fever
disease, and that a booster dose is not needed (9). This conclusion was based on a systematic review of published studies on
the duration of immunity after a single dose of yellow fever
vaccine, and on data that suggest vaccine failures are extremely
rare and do not increase in frequency with time since vaccination (10). The advisory group noted that future studies and
surveillance data should be used to identify specific risk groups,
such as persons infected with human immunodeficiency virus
(HIV) or infants, who might benefit from a booster dose. In
May 2014, the World Health Assembly adopted the recommendation to remove the 10-year booster dose requirement
from the International Health Regulations by June 2016 (11).
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Yellow Fever Vaccine Long-term
Immunogenicity Data
No data are available on vaccine efficacy or protective antibody titers (i.e., seroprotection) related to long-term immunogenicity after yellow fever vaccination. Benefits considered
critical in assessing the need for booster doses of yellow fever
vaccine for U.S. travelers or laboratory workers included vaccine effectiveness (i.e., a lack of vaccine failures) and evidence
of seropositivity (i.e., yellow fever virus–specific antibodies
detected in a blood sample) (3).
Vaccine effectiveness. A total of 23 vaccine failures were
identified after the administration of >540 million doses of
yellow fever vaccine (3). Of the 23 cases, five occurred <10 days
after vaccination and were excluded because most persons are
not expected to develop protective titers in that timeframe (5).
Of the remaining 18 cases, 16 (89%) occurred in persons who
reported receiving a dose of the vaccine within the previous
10 years (3). One vaccine failure occurred at 20 years and one
at 27 years post-vaccination.
Seropositivity. Thirteen observational studies provided
immunogenicity data on 1,137 persons vaccinated ≥10 years
previously (3). Using a random effects model, the estimated
seropositivity rate for persons vaccinated ≥10 years previously
was 92% (95% confidence interval [CI] = 85%–96%). Of the
164 persons vaccinated ≥20 years previously, the estimated
seropositivity rate was 80% (CI = 74%–86%).

Yellow Fever Vaccine Booster Dose Safety Data
Serious adverse events, yellow fever vaccine–associated viscerotropic disease (a severe illness similar to wild-type disease),
and yellow fever vaccine-associated neurologic disease were
considered critical risks to assess the need for yellow fever
vaccine booster doses (7).
Serious adverse events. Nine observational studies provided
data on serious adverse events for 333 million distributed
doses of yellow fever vaccine (3). Overall, 1,255 persons were
reported to have a serious adverse event after yellow fever
vaccination. For most (84%) persons, it was unknown if the
adverse event occurred after a primary or booster dose of the
vaccine. Of the 201 persons with a serious adverse event where
dose type was known, 14 (7%) of the adverse events occurred
after a booster dose of vaccine.
Viscerotropic disease. Eight observational studies provided
data on viscerotropic disease for 437 million distributed doses
of yellow fever vaccine (3). A total of 72 persons had yellow
fever vaccine–associated viscerotropic disease. Of the 31
persons where dose type was known, one (3%) had viscerotropic disease after receiving a booster dose of the vaccine; no

648

MMWR / June 19, 2015 / Vol. 64 / No. 23

BOX. Recommendations for use of yellow fever vaccine booster doses*

• A single primary dose of yellow fever vaccine provides
long-lasting protection and is adequate for most
travelers [Category A].
• Additional doses of yellow fever vaccine are
recommended for certain travelers:
–– Women who were pregnant (regardless of trimester)
when they received their initial dose of yellow fever
vaccine should receive 1 additional dose of yellow
fever vaccine before their next travel that puts them
at risk for yellow fever virus infection [Category A];
–– Persons who received a hematopoietic stem cell
transplant after receiving a dose of yellow fever
vaccine and who are sufficiently immunocompetent
to be safely vaccinated should be revaccinated before
their next travel that puts them at risk for yellow
fever virus infection [Category A];
–– Persons who were infected with human
immunodeficiency virus when they received their
last dose of yellow fever vaccine should receive a
dose every 10 years if they continue to be at risk for
yellow fever virus infection [Category A].
• A booster dose may be given to travelers who received
their last dose of yellow fever vaccine at least 10 years
previously and who will be in a higher-risk setting based
on season, location, activities, and duration of their
travel [Category B]. This would include travelers who
plan to spend a prolonged period in endemic areas or
those traveling to highly endemic areas such as rural
West Africa during peak transmission season or an area
with an ongoing outbreak.
• Laboratory workers who routinely handle wild-type
yellow fever virus should have yellow fever virus–
specific neutralizing antibody titers measured at least
every 10 years to determine if they should receive
additional doses of the vaccine. For laboratory workers
who are unable to have neutralizing antibody titers
measured, yellow fever vaccine should be given every
10 years as long as they remain at risk [Category A].
* Persons being considered for additional doses of yellow fever vaccine should
be assessed for contraindications or precautions in accordance with the
current yellow fever vaccine ACIP recommendations (7).

laboratory testing to assess vaccine causality was performed
for that case.
Neurologic disease. Eight observational studies provided
neurologic disease data for approximately 462 million
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distributed doses of yellow fever vaccine (3). A total of 218
persons had yellow fever vaccine–associated neurologic disease.
Of the 110 persons where dose type was known, three (3%)
persons reported neurologic disease after receiving a booster
dose of the vaccine.

Other relevant evidence
Pregnant women. The proportion of women who develop
yellow fever virus antibodies is variable and might be related
to the trimester in which they received the vaccine. Among
pregnant women who received yellow fever vaccine primarily
in their third trimester, 39% (32 of 83) had evidence of seroconversion to yellow fever virus at 2–4 weeks post-vaccination,
compared with 94% (89 of 95) in the general population (12).
Of 433 women vaccinated primarily in the first trimester
(mean gestational age = 5.7 weeks; CI = 5.2–6.2), 425 (98%)
developed yellow fever virus–specific neutralizing antibodies
at 6 weeks post-vaccination (13).
Hematopoietic stem cell transplant recipients. Data are
limited on safety and immunogenicity for yellow fever vaccine
in hematopoietic stem cell transplant recipients. However, data
suggest most recipients become seronegative to live viral vaccine
antigens after transplantation (14). Infectious Diseases Society
of America guidelines recommend re-administering live viral
vaccines, such as measles, mumps, and rubella vaccine and
varicella vaccine, to post-transplant patients if the recipient is
seronegative and is no longer immunosuppressed (15).
HIV-infected persons. Two published studies provide
immunogenicity data for yellow fever vaccines in HIV-infected
persons (16,17). Both studies found lower rates of yellow fever
virus–specific neutralizing antibodies among HIV-infected
persons compared with uninfected controls at 10 to 12 months
post-vaccination. Although the mechanisms for the diminished
immune response in HIV-infected persons are uncertain, an
inverse correlation exists between immune response and HIV
RNA levels and a positive correlation with CD4+ cell counts (18).
Young children. Twelve studies provided data on the initial
immune response to yellow fever vaccine in children aged
4 months–10 years (3). All studies included children who
resided in endemic areas, and 10 studies included children
who received at least one other vaccine at the same time as
yellow fever vaccine. Based on a random effects model, the
estimated seroconversion rate in 4,675 children was 93%
(CI = 88%‒96%). No difference was observed in the seroconversion rates between children aged <9 months and those
aged ≥9 months (3).
Other higher-risk groups. Over the preceding 20 years,
90% of all yellow fever cases were reported from countries in
West Africa, and epidemiologic data suggest that travelers to
West Africa are at the highest risk for travel-associated yellow

Summary
What is currently recommended?
In 2009, the Advisory Committee on Immunization Practices
(ACIP) approved yellow fever vaccine recommendations that
noted International Health Regulations require revaccination at
intervals of 10 years to boost antibody titer. Evidence from
multiple studies demonstrates that yellow fever vaccine
immunity persists for many decades and might provide
life-long protection.
Why are the recommendations being modified now?
The World Health Organization Strategic Advisory Group of
Experts in Immunization concluded in April 2013 that a
single primary dose of yellow fever vaccine is sufficient to
confer sustained immunity and lifelong protection against
yellow fever disease, and a booster dose of the vaccine is not
needed. In May 2014, the World Health Assembly adopted
the recommendation to remove the 10-year booster dose
requirement from the International Health Regulations by
June 2016. Once the International Health Regulations are
updated, the current statement in the ACIP recommendation
will no longer be relevant.
What are the new recommendations?
A single primary dose of yellow fever vaccine provides longlasting protection and is adequate for most travelers. The
recommendations also provide considerations and recommendations for at-risk laboratory personnel and certain travelers to
receive additional doses of yellow fever vaccine.

fever (5). Persons traveling to an area with an ongoing outbreak,
persons traveling for a prolonged period in an endemic area,
and laboratory workers who routinely handle wild-type yellow
fever virus are also considered to be at higher risk for yellow
fever virus exposure and disease than other persons for whom
yellow fever vaccine is recommended.

Rationale for Yellow Fever Vaccine Booster Dose
Recommendations
The GRADE evaluation found that there are few vaccine failures documented after a primary dose of yellow fever vaccine,
most (92%) primary vaccine recipients maintain detectable
levels of neutralizing antibodies ≥10 years post-vaccination, and
few serious adverse events have been reported after a booster
dose of yellow fever vaccine (3). Based on the available data,
ACIP voted to no longer recommend booster dose of yellow
fever vaccine for most travelers, because a single dose of yellow
fever vaccine provides long-lasting protection (Box). However,
additional doses of yellow fever vaccine are recommended for
certain populations (i.e., pregnant women, hematopoietic
stem cell transplant recipients, and HIV-infected persons) who
might not have as robust or sustained immune response to yellow fever vaccine compared with other recipients. Furthermore,
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additional doses may be given to certain groups believed to be
at increased risk for yellow fever disease either because of their
location and duration of travel or because of more consistent
exposure to virulent virus (i.e., laboratory workers). ACIP
meeting minutes are available at http://www.cdc.gov/vaccines/
acip/meetings/meetings-info.html.
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